期刊文献+

冠心病患者血清胱抑素C及白介素-18检测的临床意义 被引量:7

The Clinical Significance of Detection of CysC and IL-18 in Patients with Coronary Heart Disease
下载PDF
导出
摘要 目的:通过联合测定冠心病患者血清胱抑素C(Cystatin C,CysC)和白介素-18(interleu-kin,IL-18)水平,探讨CysC和IL-18在冠心病病情评估中的意义。方法:应用全自动生化分析仪和酶联免疫吸附法(ELISA)测定58例冠心病患者血清CysC和IL-18水平,同时与40例正常对照组检测结果进行比较。结果:冠心病各组患者血清CysC和IL-18水平较对照组显著升高,差异有统计学意义(P<0.01);冠心病各组患者血清IL-18水平间相互比较,差异有统计学意义(P<0.01);血清CysC高水平组患者发生二次心血管事件的发病率明显高于低水平组(X2=4.392,P<0.05)。结论:联合测定冠心病各组患者血清CysC和IL-18水平,对冠心病的诊断、治疗及病情评估等方面具有较高的临床应用价值。 Objective: To investigate the significance of joint detection of serum levels CysC and IL-18 in patients with coronary artery disease.Method: The automatic biochemical analyzer and ELISA were used to detect the serum levels of CysC and IL-18 in 58 patients with coronary heart disease and the test results were comparing with 40 healthy controls.Result:The serum levels of CysC and IL-18 in 58 patients with coronary heart disease were significantly higher than those of healthy controls,the difference was statistically significant(P0.01).The serum levels of IL-18 compared to each other,The difference was statistically significant(P0.01).The incidence of cardiovascular events of the second in patients with high serum level of CysC was significantly higher than the low group(X2=4.392,P0.05).Conclusion:Joint detection of serum levels CysC and IL-18 in patients with coronary artery disease has a higher value of clinical application for diagnosis,treatment and disease assessment.
出处 《河北医学》 CAS 2012年第11期1536-1538,共3页 Hebei Medicine
关键词 冠心病 血清胱抑素C 白介素-18 Coronary heart disease Cystatin C Interleukin-18
  • 相关文献

参考文献8

  • 1郭东梅,胡蓉.冠心病新的危险因素研究进展[J].重庆医学,2011,40(24):2462-2465. 被引量:43
  • 2Ix JFI, Shlipak MG, Chertow GM, et al. Association of cystafin C with mortality, cardiovascular events and incident heart failure among persons with coronary heart disease: data from the heart and soul study[J]. Circulation, 2007, 115: 173-179.
  • 3C,e C, Ben F, Lu S, et al. Clinical prognostic significance of plasma cystatin C levels among patients with acute coronary syndrome [ J ]. Clin Cardiol,2009,32 ( 11 ) : 644 -648.
  • 4Garcia Acuna JM, Gonzalez-Babarro E, Gfigofian Shamagian L,et al. Cystatin C provides more information than other renal function parameters for stratifying risk in patients with acute coronary syndrome[J]. Rev Esp Cardiol,2009,62(5 ) : 510-519.
  • 5Kim EH, Yu JH, Lee SA, et al. Lack of association between serum eystafin C levels and coronary artery disease in diabetic patients[ J]. Korean Diabetes,2010,34(2) :95-100.
  • 6Chen MC, Chen C J, Yang CH. et al. Interleukin-18:a strong predictor of the extent of coronary artery disease in patients with unstable anglna[ J ]. Heart Vessels,2007,22 (6) : 371 - 375.
  • 7Furtado MV, Rossini AP, Campani RB, et al. Interleukin - 18:an independent predictor of cardiovascular events in patients with acute coronary syndrome after 6 months of follow up[ J]. Coron Artery Dis,2009,20(5) :327-331.
  • 8Hartford M,Wiklund O,Huhon LM,et al. Interleukin 18 as a predictor of future events in patients with acute coronary syndromes[J]. Arterioscler Thromb Vase Biol,2010,30(10) : 2O39 -2O46.

二级参考文献25

  • 1Mien-Cheng Chen,Chien-Jen Chen,Cheng-Hsu Yang,Chiung-Jen Wu,Chih-Yuan Fang,Yuan-Kai Hsieh,Hsueh-Wen Chang.Interleukin-18: a strong predictor of the extent of coronary artery disease in patients with unstable angina[J]. Heart and Vessels . 2007 (6)
  • 2Goswami B,,Rajappa M,Mallika V,et al.Apo-B/apo-AIratio:a better discriminator of coronary artery diseaserisk than other conventional lipid ratios in Indian patientswith acute myocardial infarction. Acta Cardiologica . 2008
  • 3Aksu H,Ozer O,Unal H,et al.Significance of meanplatelet volume on prognosis of patients with and withoutaspirin resistance in settings of non-ST-segment elevatedacute coronary syndromes. Blood Coagulation and Fibrinolysis . 2009
  • 4Chu H,Chen WL,Huang CC,et al.Diagnostic perform-ance of mean platelet volume for patients with acute coro-nary syndrome visiting an emergency department with a-cute chest pain:the Chinese scenario. Emergency Medicine Journal . 2011
  • 5Hartford M,Wiklund O,Hultén LM,et al.Interleukin-18as a predictor of future events in patients with acute coro-nary syndromes. Arteriosclerosis and Thrombosis . 2010
  • 6Liu J,Ma L,Yang J,et al.Increased serum cathepsin S inpatients with atherosclerosis and diabetes. Atherosclerosis . 2006
  • 7Kim EH,Yu JH,Lee SA,et al.Lack of association be-tween serum cystatin C levels and coronary artery diseasein diabetic patients. Korean Diabetes J . 2010
  • 8Schwertner HA,Jackson WG,Tolan G.Association of low serum concentration of bilirubin with increased risk of coronary artery disease. Clinical Chemistry . 1994
  • 9Sierra-Johnson J,Fisher RM,Romero-Corral A,et al.Con-centration of apolipoprotein B is comparable with the apoli-poprotein B/apolipoprotein A-I ratio and better than routine clinical lipid measurements in predicting coronary heart dis-ease mortality:findings from a multi-ethnic US population. European Heart Journal . 2009
  • 10Walldius G,J ungner I,Aastveit AH, et al.The apoB/apoAI ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk. Clinical Chemistry and Laboratory Medicine . 2004

共引文献42

同被引文献71

  • 1Stulak JM, Dearani JA, Burkhart HM, et al. Coronary artery disease in adult congenital heart disease:outcome after coronary artery by- pass grafting[ J]. Ann Thorac Surg ,2012,93 ( 1 ) : 116 - 122.
  • 2Long J, Luckraz H, Thekkudan J, et al. Heart team discussion in managing patients with coronary artery disease : outcome and repro- ducibility [ J ]. Interact Cardiovasc Thorac Surg, 2012, 14 ( 5 ) : 594 - 598.
  • 3Bokeriia LA, Golukhova EZ, Sigaev IIu, et al. Modem approach to- wards surgical treatment of coronary heart disease in diabetic patients [ J ]. Vestn Ross Akad Med Nauk,2012 ( 1 ) :20 - 26.
  • 4Pereg D, Tiresh A, Elis A, et al. Mortality and coronary heart disease in euthyreid patients[ J]. Am J Med ,2012,125 ( 8 ) :826.
  • 5Argraves KM, Gazzolo PJ, Groh EM, et al. High density lippprotein-assoeiated shpingosine 1-phosphate promotes endothelial barrier function[J]. J Bio Chem, 2008, 283 (36) : 25074-25081.
  • 6Thilmeier G, Schmidt C, Herrmann J, et al. High-density lipoproteins and their constituent, sphingosine-l-phos- phate,directly protect the heart against ischemia/reperfu- sion injury in vivo via the S1P3 lysophospholipid receptor [J]. Circulation, 2006,114(13) : 1403-1409.
  • 7Nofer JR, Bot M, Brodde M, et al. FTY720, a sunthetic shpingosine 1 phosphate analogue,inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient miee[J]. Circulation,2007,115(4):501-508.
  • 8Kang SJ, Mintz GS, Park DW, et al. Mechanisms of in-stent restenosis after drug-eluting stent implantation: intravaseular ultrasound analysis[J]. Circ Cardiovasc,2011,4(1):9-14.
  • 9Nofer JR, van der Giet M, Tolle M, et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid re- ceptor SIP3[J]. J Clin Invest, 2004,113 (4): 569-581.
  • 10Lan T, Bi H, Liu W, et al. Simultaneous determination of sphingosine and sphingosine 1-phosphate in biological samples by liquid chromatography-tandem mass spec- trometry[J]. J Chromatogr B Analyt Technol Biomed Life Sci,2011,879 (7/8) :520-525.

引证文献7

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部